Chordia Therapeutics Inc.
190A・Growth Market・Pharmaceuticals
Governance
The company is structured as a company with an audit and supervisory committee. The board of directors comprises 6 members (including 5 outside directors, an outside director ratio of 83.3%). The audit and supervisory committee consists entirely of 3 outside directors. The annual securities report contains no mention of the establishment of a nomination committee or a compensation committee.
Risk Management
The Representative Director serves as the overall officer responsible for risk management, including sustainability, with the Management Administration Department as the responsible division. The company has established a Compliance Management Regulation, an internal whistleblowing system, and an Emergency Response Regulation, building a framework for regular reporting to the Management Meeting, the Board of Directors, and the Audit and Supervisory Committee. It also collaborates with external experts (law firms, patent firms, accounting firms, etc.).
Shareholder Returns
No dividends paid since establishment. No dividend planned for FY2026 (ending August 2026) either (annual dividend of ¥0.00). Priority remains on securing funds for R&D activities for the time being, with no dividend implementation planned. Once stable earnings are secured in the future, the basic policy will be to pay a year-end dividend once annually (record date August 31).
Dividend Policy
The company has not paid dividends since its establishment, and its policy is to prioritize securing funds to sustain R&D activities for the time being, with no dividends to be paid. The forecast annual dividend for FY2026 (ending August 2026) is ¥0.00. If the company becomes able to secure stable earnings in the future and generates sufficient profit to cover R&D funding needs, its basic policy will be to pay a year-end dividend once annually with a record date of August 31, and it will also consider an interim dividend with a record date of the end of February.
ESG
Under the mission of "Tomorrow is Another Day – Realizing a Society That Feels Hope for Tomorrow," the company's basic policy centers on contributing to society through cancer treatment. Regarding human capital, the company promotes diverse hiring and the creation of a comfortable working environment, but quantitative indicators and targets have not yet been set. For environmental risks such as climate change, the company has established a system in which the Management Administration Department identifies and monitors such risks.
Last updated: November 21, 2025